# First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)

> **NCT04638790** · PHASE3 · RECRUITING · sponsor: **State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia** · enrollment: 300 (estimated)

## Conditions studied

- Hodgkin Lymphoma, Adult

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Bleomycin
- **DRUG:** Vinblastine
- **DRUG:** Dacarbazine
- **DRUG:** Etoposide
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Vincristine
- **DRUG:** Dexamethasone
- **DRUG:** Dacarbazine

## Key facts

- **NCT ID:** NCT04638790
- **Lead sponsor:** State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-02-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2024-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04638790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04638790, "First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04638790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*